- Animal Models (AM) shared resource The Animal Models Shared Resource (AM) assists LCCC members with all aspects of mouse-related research. It consists of three arms that seamlessly interact to provide a broad range of experimental approaches and expert advice. The SR staff assists with complex surgical techniques, animal handling, xenograft tumor models, colony management, therapeutic trials, imaging studies, allele phenotyping and the design and production of genetically engineered mice (GEM) and provides access to a colony of immunocompromised animals for PDX studies. This SR adds value to the Cancer Center by enabling cost- efficient murine testing for all members including those without significant infrastructure and expertise for animal work. The SR is co-directed by Charlene Ross, Dale Cowley and David Darr, with faculty co-advisors. Ms. Santos has served as a Facility Director providing expertise in mouse xenograft models while Dr. Cowley has led efforts in the design and generation of GEM models since 2005. Mr. Darr has been added to the leadership since the last cycle to add expertise and administrative oversight in pre-clinical testing in GEM models and expand SR capabilities. The AM has grown significantly during the last cycle, driven largely by increased NIH funding to UNC investigators, the 50% increase in campus animal space and a strategic plan featuring cancer genetics and preclinical therapeutics testing. The SR has 61 LCCC users, the remaining 22 Non-member users are collaborators located at Cancer Centers across the country. Importantly, Marsico Hall opened in late 2014 with 2,000 additional cages for longitudinal mouse therapy and imaging protocols. The availability of this space has also enhanced the interactions between this SR and the Imaging SR. The AM has become the nexus for Cancer Center members exploiting the power of GEMs and xenograft tumor models for basic and translational cancer research. The result is publications in high impact journals such as Cell, JNCI, JCI, Nature, Proc. Natl. Acad. Sci. USA., Cancer Cell, Cancer Discovery and CCR. We request an increased budget of 226,107 that will represent 10% of the total AM budget to promote expanded use.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-42
Application #
9391962
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
42
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468
Zhang, Jing; Wu, Tao; Simon, Jeremy et al. (2018) VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361:290-295

Showing the most recent 10 out of 1525 publications